Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Epigral Limited is an Indian specialty chemicals manufacturer operating in the Basic Materials sector with significant exposure to agrochemical intermediates, pharmaceutical ingredients, and industrial chemical production. The company has demonstrated exceptional recent growth (34.7% revenue, 82.6% net income YoY) with strong margins (41.8% gross, 37.3% operating) and healthy cash generation ($2.5B FCF), though the stock has declined sharply (-45.2% over 1 year) likely reflecting sector-wide valuation compression or commodity input cost pressures.
Epigral generates revenue through contract manufacturing and sale of specialty chemical intermediates to downstream agrochemical, pharmaceutical, and industrial customers. The business model relies on technical expertise in complex chemical synthesis, regulatory compliance (GMP, environmental standards), and long-term supply agreements with multinational customers seeking China+1 diversification. Pricing power derives from switching costs (customer qualification cycles of 12-24 months), proprietary process chemistry, and capacity constraints in specialty segments. The 41.8% gross margin suggests value-added chemistry rather than commodity production.
New customer contract wins and capacity expansion announcements, particularly with multinational agrochemical/pharma companies seeking supply chain diversification from China
Raw material cost inflation (crude oil derivatives, natural gas, specialty feedstocks) and ability to pass through costs via contractual mechanisms
Capacity utilization rates across manufacturing facilities - specialty chemical plants typically need 70-80% utilization for profitability
Regulatory developments affecting agrochemical approvals or pharmaceutical API sourcing requirements in key export markets (US, EU)
Chinese specialty chemical supply dynamics and competitive pricing pressure from state-subsidized producers
Environmental regulation intensification in India requiring costly emissions control upgrades, wastewater treatment, and hazardous waste management - specialty chemical manufacturing faces increasing ESG scrutiny
Technological disruption from continuous flow chemistry, biocatalysis, or green chemistry alternatives that could obsolete existing batch manufacturing infrastructure
Long-term agrochemical demand pressure from precision agriculture, biological pest control adoption, and regulatory restrictions on synthetic pesticides in developed markets
Chinese specialty chemical producers regaining competitiveness through government subsidies, vertical integration, or capacity restarts after environmental crackdowns ease
Customer backward integration as large agrochemical/pharma companies build captive manufacturing to secure supply chains and capture margin
Pricing pressure from overcapacity as multiple Indian specialty chemical companies simultaneously expand production in similar chemistry platforms
Working capital intensity risk - the $1.9B capex alongside growth could strain cash if customer payment terms extend or inventory builds due to demand slowdown
Foreign exchange exposure on export revenues (likely 50-70% of sales to US/EU customers) versus rupee-denominated costs, though this can be hedged
Contingent environmental liabilities from historical manufacturing operations or waste disposal that could require remediation
moderate-to-high - Agrochemical demand correlates with crop prices and farming economics (influenced by global food demand, weather patterns). Pharmaceutical intermediate demand is more stable but sensitive to generic drug pricing and healthcare spending. Industrial chemical demand directly tracks manufacturing PMI and industrial production. The 34.7% revenue growth suggests cyclical upswing exposure, while the recent 45% stock decline may reflect concerns about demand normalization.
Rising interest rates create moderate headwinds through higher working capital financing costs (specialty chemicals require significant inventory and receivables financing) and capex financing for capacity expansion. The $1.9B capex run-rate suggests active expansion that becomes more expensive in higher rate environments. However, the low 0.26 debt/equity ratio limits direct balance sheet impact. Valuation multiples (currently 8.2x EV/EBITDA) compress as rates rise and investors demand higher equity risk premiums for cyclical industrials.
Moderate - Customer credit quality matters as specialty chemical contracts involve 60-90 day payment terms. Tightening credit conditions could stress agrochemical distributors or smaller pharmaceutical customers. However, the 1.31 current ratio and strong cash generation ($4.4B operating cash flow) provide internal liquidity buffer. Supplier financing for raw material purchases becomes more expensive in tight credit environments.
growth - The 34.7% revenue growth, 82.6% net income growth, and 79.6% EPS growth attract growth investors seeking exposure to India's specialty chemical sector benefiting from China+1 supply chain diversification. However, the 45% decline suggests momentum investors have exited. The 5.7% FCF yield and 1.8x P/S ratio (low for high-growth) may attract value investors viewing the selloff as overdone. The 18.5% ROE and strong cash generation appeal to quality-focused growth-at-reasonable-price (GARP) investors.
high - The -34.5% 3-month and -47.2% 6-month returns demonstrate elevated volatility typical of mid-cap specialty chemical stocks with commodity input exposure, customer concentration risk, and emerging market listing. Indian small/mid-cap industrials typically exhibit beta of 1.2-1.5x to broader market. Quarterly earnings volatility driven by raw material cost timing, customer order lumpiness, and forex fluctuations creates trading opportunities but requires higher risk tolerance.
